The 2026 CDISC China Interchange has brought clinical research data specialists and industry stakeholders together in Shanghai to discuss evolving standards, regulatory practices and artificial intelligence-enabled workflows.
The programme was hosted at the Novartis Shanghai Campus, with training sessions held on 12–13 August, the main China Interchange conference on 14 August and a user group meeting on 15 August.
The event focused on the role of data standards in supporting increasingly complex clinical development programmes and enabling consistent exchange and analysis of clinical research information.
Experts and industry participants discussed developments in Clinical Data Interchange Standards Consortium standards alongside regulatory best practices and approaches to clinical data management.
Artificial intelligence-enabled workflows were also part of the user group programme, reflecting the growing use of automation and AI across clinical research operations.
The discussions examined how emerging digital approaches can be incorporated while maintaining structured and standardised clinical data suitable for regulatory and research applications.
Clinical data standards are increasingly relevant as sponsors operate trials across multiple countries, technology platforms and research organisations, creating greater demand for interoperable and consistently structured datasets.
The meeting also provided a forum for companies, researchers and clinical data specialists to exchange approaches to regulatory compliance and implementation of new standards.
Novartis served as host sponsor for the meeting, while the education training programme was hosted by BeOne Medical.
Other participating sponsors included Caidya, GCP ClinPlus, Taimei Intelligence R&D, Jingqiang and SAS.
The 2026 programme concluded with the China Interchange User Group Meeting on 15 August, focusing on the latest CDISC developments, AI-enabled workflows, regulatory practices and clinical data-management approaches.
